Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Depomed Inc    DEPO

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Analysis summary4-Traders Strategies

Back to the USD 7 level

share with twitter share with LinkedIn share with facebook
share via e-mail
02/13/2013 | 03:19pm

From a fundamental viewpoint, the company is strong. The Thomson Reuters consensus revised regularly upward EPS estimates of the company for the current year. In addition the publication of the third quarter of 2012 showed an incredible growth of turnover by more than 100% at USD 33.3 million compared to the same period the previous year. The growing business should allow the security to continue its ascension.

Technically, the security is in an uptrend on all time scales. Prices are coming back to the USD 6.6 short term support, level corresponding to the 20-day moving average. This configuration should allow the stock to bounce towards the USD 7 long term resistance, which will be the first target price.

According to both technical and fundamental elements, it seems opportune to take a long position at the current price. The bullish trend should allow the security to reach the USD 7 resistance. A stop loss will be placed under the USD 6.6 short term support to avoid a downtrend.


© Zonebourse.com 2013
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Company
Manufactures and distributes pharmaceutical productsDepomed, Inc. is a pharmaceutical company, which manufactures and distributes pharmaceutical products to treat pain and other central nervous system conditions.Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA.The company... 
Sector
Pharmaceuticals
Calendar
11/06Earnings Release
Financials ($)
Sales 2017 407 M
EBIT 2017 109 M
Net income 2017 -82,7 M
Debt 2017 606 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 2,45x
EV / Sales 2018 2,30x
Capitalization 391 M
Chart DEPOMED INC
Duration : Period : Day
Depomed Inc Technical Analysis Chart | DEPO | US2499081048 | 4-Traders
Duration : Period : Week
Depomed Inc Technical Analysis Chart | DEPO | US2499081048 | 4-Traders
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes